Generic Cartia Xt

Generic Name: Generic cartia xt

What is Generic Cartia Xt?

Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor. Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, dyspepsia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase see WARNINGS, Acute Hepatic Injurythirst, vomiting, weight increase.

Other: Amblyopia, CPK increase, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties. The following postmarketing events have been reported infrequently in patients receiving diltiazem: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema including facial or periorbital edemaasystole, erythema multiforme including Stevens-Johnson syndrome, toxic epidermal necrolysisexfoliative dermatitis, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, photosensitivity including lichenoid keratosis and hyperpigmentation at sun-exposed skin areaspurpura, retinopathy, myopathy, and thrombocytopenia.

In addition, events such as myocardial infarction have been observed which are not readily distinguishable from the natural history of the disease in these patients. A number of well-documented cases of generalized rash, some characterized as leukocytoclastic vasculitis, have been reported.

However, a definitive cause and effect relationship between these events and diltiazem therapy is yet to be established. To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.

The toxic dose in man is not known.

Although clinical data are lacking, it may be prudent to exercise caution when co-administering voriconazole and any calcium-channel blocker.

Yohimbine: Yohimbine a selective central alpha 2-adrenoceptor antagonist can increase blood pressure, and therefore can antagonize the therapeutic action of antihypertensive drugs in general. Use with particular caution in hypertensive patients with high or uncontrolled BP. Zafirlukast: Zafirlukast and zileuton are respiratory antiinflammatory agents which can theoretically inhibit CYP3A4 metabolism of calcium-channel blockers, CYP3A4 substrates.

Zileuton: Zileuton is a respiratory antiinflammatory agent which can theoretically inhibit CYP3A4 metabolism of diltiazem, a CYP3A4 substrate. Ziprasidone: Diltiazem may reduce ziprasidone metabolism via inhibition of CYP3A4 isoenzymes. In addition, additive hypotensive effects are possible if ziprasidone is used concurrently with antihypertensive agents. Zolpidem: It is advisable to closely monitor zolpidem tolerability and safety during concurrent use of diltiazem, a moderate CYP3A4 inhibitor, since CYP3A4 is the primary isoenzyme responsible for zolpidem metabolism.

There is evidence of an increase in pharmacodynamics effects and systemic exposure of zolpidem during co-administration with some potent inhibitors of CYP3A4, such as azole antifungals. Zonisamide: Zonisamide is a weak inhibitor of P-glycoprotein P-gpand diltiazem is a substrate of P-gp. There is theoretical potential for zonisamide to affect the pharmacokinetics of drugs that are P-gp substrates.

Use caution when starting or stopping zonisamide or changing the zonisamide dosage in patients also receiving drugs which are P-gp substrates.

How should I take Generic Cartia Xt?

Erlotinib is primarily metabolized by CYP3A4, and to a lesser extent by CYP1A2. Erythromycin: Avoid administration of erythromycin and a calcium-channel blocker, particularly in geriatric patients.

Coadministration has been associated with an increased risk of hypotension and shock. Azithromycin may be preferred if the use of a macrolide antibiotic is necessary in a patient receiving calcium-channel blocker therapy. Erythromycin may also decrease the clearance of calcium-channel blockers e.

What should I avoid while taking Generic Cartia Xt?

Bosutinib is a CYP3A4 substrate and diltiazem is a moderate CYP3A4 inhibitor. In a cross-over trial in 18 healthy volunteers, the Cmax and AUC values of bosutinib were increased 1. Bretylium: Concomitant use of bretylium with other antiarrhythmis, such as diltiazem, can have additive, antagonistic, or synergistic electrophysiologic, pharmacodynamic, or toxic effects, including hypotension.

Combined antiarrhythmic therapy may necessitate a reduction in antiarrhythmic drug dosages, to decrease the potential for toxicity. Diltiazem is a moderate inhibitor of CYP3A4. If diltiazem is used in combination with brexpiprazole and a moderate to strong CYP2D6 inhibitor, the brexpiprazole dose should be adjusted and the patient should be carefully monitored for brexpiprazole-related adverse reactions.

Brigatinib: Monitor for reduced response to diltiazem if coadministration of brigatinib is necessary. Dosages of diltiazem may need to be adjusted while the patient is receiving brigatinib.

Generic Cartia Xt side effects

Hydrocodone is metabolized by CYP3A4. Concomitant administration of a CYP3A4 inhibitor, such as diltiazem, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects. Concurrent administration of oxycodone and voriconazole, another CYP3A4 inhibitor, increased oxycodone AUC by 3.

The manufacturer of afatinib recommends permanent discontinuation of therapy for severe or intolerant adverse drug reactions at a dose of 20 mg per day, but does not address a minimum dose otherwise. Aldesleukin, IL-2: Calcium channel blockers may potentiate the hypotension seen with aldesleukin, IL 2.

Alemtuzumab: Alemtuzumab may cause hypotension. Careful monitoring of blood pressure and hypotensive symptoms is recommended especially in patients with ischemic heart disease and in patients on antihypertensive agents.

Common Generic Cartia Xt ide effects may include:

  • If these drugs are used together, closely monitor for increased side effects of diltiazem.

  • The dose may be increased slowly over time until treatment goals are achieved.

  • You may report side effects to FDA at 1-800-FDA-1088.

  • Etodolac: If nonsteroidal anti-inflammatory drugs NSAIDs and an antihypertensive drug are concurrently used, carefully monitor the patient for signs and symptoms of renal insufficiency and blood pressure control.

The change in the pharmacodynamic marker pSTAT3 inhibition was consistent with the increase in exposure. Sapropterin: Caution is advised with the concomitant use of sapropterin and diltiazem as coadministration may result in increased systemic exposure of diltiazem. If these drugs are used together, closely monitor for increased side effects of diltiazem.

Saquinavir: Saquinavir may inhibit the metabolism of other medications that are metabolized via cytochrome P450 3A4. Although drug interaction studies have not been conducted, the serum concentration of diltiazem may be increased with concomitant administration of saquinavir.

Where can I get more information?

  • Diltiazem is a P-glycoprotein P-gp inhibitor and osimertinib is a P-gp substrate in vitro.

  • Call your doctor for medical advice about side effects.